Skip to content
Back to news

Digital and data, the pillars of our transformation

For companies to remain competitive and sustainable in a rapidly changing environment, they need to be able to transform and develop, by focusing on innovation across the entire value chain. In particular, disruptive digital technologies (artificial intelligence, big data, etc.) are a key component of competitiveness! That’s why, at Servier, we’re have embarked upon a massive digital transformation, which is already delivering results. Below, we share an update on our ambitions and a recap of what we’ve accomplished so far.

We desire to accelerate therapeutic progress through digital transformation. Our ambition is therefore to be among the best digital performers in the pharmaceutical sector. Digital technology will enable us to improve our performance across the entire value chain by:

  • Improving our chances of success in drug discovery;
  • Reducing the time it takes to develop and bring to market our therapeutic solutions;
  • Transforming our business model with new services for patients and health care professionals.

“In this new technological era, digital transformation and data are vital if we are to keep step with patients’ medical needs, achieve our goals, and safeguard our independence. With optimized, digitized end-to-end processes and advanced analytics, digital technology and data offer unprecedented opportunities to reduce our R&D time-to-market and support our long-term innovation.”

Virginie Dominguez, Executive Vice President Digital Data and Information Systems

We also use digital technologies and data to improve our efficiency: we were the first French pharmaceutical group to enter into a successful strategic partnership with Google. We now have at our disposal a Group data platform (One Data Platform) built on Google Cloud technology. This has enabled us to deliver several high value-added use cases for our business lines.

Boosting R&D productivity with digital technologies

In R&D, data and digital technologies not only increase the probability of success in discovering new therapeutic solutions, but also speed up development and subsequent time to market.

We recently teamed up with Owkin, a Franco-American biotech company that specializes in applying artificial intelligence (AI) to new drug discovery and development and to diagnostic tools. Together, our objective is to use AI to advance and expedite better-targeted treatments in multiple therapeutic areas, particularly oncology.

AI, the next step in therapeutic innovation!

Over the last few years, medical research has been undergoing a fundamental metamorphosis as a result of the advent of AI-powered data processing tools. AI clears the way for considerable time savings in drug discovery, as well as for more personalized medicine.

Our teams can also draw on FederateS, a data aggregation platform for researchers, and SCORE (Servier Clinical Operation Reveal Evidence), a program that improves clinical development efficiency for the benefit of patients.

Improving patient adherence to treatment

One of our main priorities at Servier is overcoming medication nonadherence, particularly in the case of chronic pathologies like cardiovascular diseases.

Advances in digital technologies are offering up unprecedented possibilities for improving patients’ lives. One specific approach is known as the “beyond the pill,” and when new technologies are used as a complement to the patient’s medical treatment, it enables them to follow an integrated, holistic digital treatment plan. Sometimes these approaches are implemented in partnership with start-ups and Big Tech companies, which can lead to mutually enriching collaborations.

 “Therapeutic adherence: the missing piece to treat chronic diseases”: Read the opinion piece by Arnaud Lallouette, Executive Vice President Global Medical & Patient Affairs at Servier.